Medical Information Notice
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider. Read full disclaimer
Opicapone
Quick Facts
- Generic Name
- Opicapone
- Brand Names
- Ongentys
- Drug Class
- COMT inhibitor
- FDA Approved
- 2020
How It Works
Opicapone is a third-generation, once-daily catechol-O-methyltransferase (COMT) inhibitor that prevents the peripheral breakdown of levodopa, extending its duration of action and reducing wearing-off motor fluctuations. It acts exclusively in the periphery and provides sustained, near-complete COMT inhibition throughout the 24-hour dosing interval — a significant pharmacological advantage over entacapone, which requires dosing with each levodopa administration.
What to Expect as a Patient
Opicapone is remarkably simple to take: one capsule at bedtime, at least one hour after your last levodopa dose. You will likely notice smoother, longer-lasting on-periods within the first few days. Because opicapone increases the effectiveness of levodopa, you may experience more involuntary movements (dyskinesia) initially — your doctor may reduce your levodopa dose by 10-20% to compensate. Unlike entacapone, opicapone does not typically cause urine discoloration or significant diarrhea. Constipation and dry mouth are the most common side effects. No liver monitoring is required (unlike tolcapone).
Typical Dosing
50mg once daily at bedtime, taken at least one hour before or after the last levodopa dose of the day. No titration needed.
Dosing is individualized by the prescribing physician. The information above is for general reference only.
Common Side Effects
- Dyskinesia
- Constipation
- Elevated creatine kinase
- Hypotension
- Weight decrease
- Dry mouth
Serious Side Effects
Seek medical attention immediately if you experience any of the following:
- Hallucinations
- Impulse control disorders
- Rhabdomyolysis (very rare)
Contraindications
- Pheochromocytoma
- Paraganglioma
- Concurrent nonselective MAO inhibitors
Food Interactions
Must be taken at bedtime, at least 1 hour before or after levodopa doses. Food does not significantly affect absorption. The bedtime dosing ensures COMT inhibition is established before the first levodopa dose the next morning.
Drug Interactions
The following interactions have been documented with Opicapone. Always inform your healthcare provider about all medications you are taking.
Opicapone inhibits COMT, extending levodopa action similar to entacapone.
Clinical effects: May increase dyskinesia and levodopa side effects.
Management: Reduce levodopa dose if dyskinesia develops. Take opicapone at bedtime, separate from levodopa.
Two COMT inhibitors should not be combined. No additional benefit and increased risk of adverse effects including hepatotoxicity from tolcapone.
Clinical effects: Excessive COMT inhibition, increased diarrhea risk, hepatotoxicity (tolcapone), enhanced levodopa-related adverse effects.
Management: Use only one COMT inhibitor. Switch directly between agents without overlap. If switching to tolcapone, initiate liver function monitoring.
Two COMT inhibitors provide no additional benefit over one and increase the risk of excessive COMT inhibition and levodopa-related side effects.
Clinical effects: Excessive COMT inhibition, increased risk of diarrhea, dyskinesia, nausea, and orthostatic hypotension.
Management: Use only one COMT inhibitor. Opicapone may be preferred due to once-daily dosing. Switch directly without overlap.
COMT inhibitor with MAO-B inhibitor increases overall dopaminergic tone when used with levodopa, potentially increasing side effects.
Clinical effects: Increased risk of dyskinesia, nausea, orthostatic hypotension, and hallucinations.
Management: Combination can be used but requires careful monitoring. May need to reduce levodopa dose. Both are commonly used as levodopa adjuncts.
How Opicapone Compares to Alternatives
Opicapone is the newest and most convenient COMT inhibitor, requiring only once-daily dosing at bedtime. Compared to entacapone: opicapone provides similar or slightly superior off-time reduction with dramatically simpler dosing (once daily vs. with each levodopa dose). A real-world study showed fewer neurology visits with opicapone. Opicapone does not cause the characteristic brownish-orange urine discoloration seen with entacapone. Compared to tolcapone: opicapone has no hepatotoxicity risk and requires no liver monitoring, making it much safer. Tolcapone may still be more potent (reducing off-time by approximately 2 hours/day vs. 1.5-1.9 hours for opicapone) and is reserved for patients who fail both entacapone and opicapone.
When Is Opicapone Used by Disease Stage?
Not used in early PD without levodopa. Mid-stage PD (Stage 2.5-3): Primary role — added when wearing-off motor fluctuations develop. Increasingly prescribed as the first-choice COMT inhibitor due to once-daily convenience and favorable safety profile. Advanced PD (Stages 4-5): Continued as part of complex medication regimens. The once-daily dosing is particularly advantageous for patients managing multiple medications and for caregivers managing complex schedules.
Additional Notes
Once-daily dosing represents a major convenience advantage over entacapone (which requires dosing with each levodopa dose, up to 8 times daily). The BIPARK-I trial demonstrated that opicapone 50mg reduced off-time by 1.9 hours/day vs. 1.4 hours for placebo, comparable to entacapone. A 2023 real-world comparison found opicapone users had 18.5% fewer neurology visits than entacapone users at 6 months. No hepatotoxicity risk (unlike tolcapone).
Clinical Perspective
Opicapone represents the state of the art in COMT inhibition: potent, once-daily, and safe. It addresses the two main weaknesses of its predecessors — entacapone's inconvenient with-every-dose schedule and tolcapone's hepatotoxicity risk — without sacrificing efficacy. The real-world evidence showing fewer neurology visits compared to entacapone suggests that the pharmacological advantage of sustained COMT inhibition translates into clinical benefit. For newly diagnosed wearing-off, opicapone is increasingly the COMT inhibitor of first choice.
This perspective is based on published clinical evidence and guidelines. Individual treatment decisions should always be made with your neurologist.
Sources
- [1]Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial (BIPARK-I). JAMA Neurol. 2017;74(2):197-206
- [2]Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson disease and end-of-dose motor fluctuations. Lancet Neurol. 2016;15(2):154-165
- [3]Rocha JF, Ferreira JJ, Falcao A, et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev. 2016;5(3):232-240
- [4]Tanner CM, Ostrem JL. Parkinson disease. N Engl J Med. 2024;391(5):442-452
- [5]Muller T. Catechol-O-methyltransferase inhibitors in Parkinson disease. Drugs. 2015;75(2):157-174
Share this article